🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07567482
Recruiting Not applicable

Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease

NCT07567482 · tracked via the Priya Life Science Canada tracker
Sponsor
Centre intégré de santé et de services sociaux de l'Outaouais
Phase
Not applicable
Started
2026-04-30
Last updated
2026-05-13

Condition(s) studied

Parkinson's Disease (PD)Healthy Aging

Investigational drug(s) / intervention(s)

Exoskeleton

Exoskeleton: The exoskeleton assistance in condition 2 will correspond to the preferred assistance level determined during the first session using an iterative approach. For conditions 3 and 4, four exoskeleton parameters will be adjusted: eccentric load assistance, concentric load assistance, assistance during lower-limb flexion in the swing phase, and assistance during lower-limb extension in the swing phase. The increased and decreased assistance conditions will correspond to an increase and a decrease of 3 Nm, respectively, for each of these parameters. A minimum assistance of 1 Nm per parameter will be maintained when the baseline preferred assistance level is low. During condition 5, the exoskeleton will be set to free mode, meaning that no assistance will be provided, but motor resistance will be eliminated.

Study summary

This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility limitations. Participants will attend two laboratory sessions. The first session includes clinical assessments, fitting and familiarization with the exoskeleton, and interviews to explore user perceptions. The second session involves performing functional mobility tasks (e.g., walking, standing, turning) with and without the exoskeleton and under different assistance levels, while movement is measured using wearable sensors.

The study will assess the immediate effects of the exoskeleton on mobility, compare assistance levels, identify which participants benefit most, and explore user experience and acceptability. Findings will help inform the development and implementation of assistive technologies to support mobility in healthy aging and in individuals with Parkinson's disease.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Participants with Parkinson's disease Inclusion Criteria: * Ability to walk for at least 30 minutes with or without minimal aid * Diagnosis of idiopathic Parkinson's disease * Hoehn and Yahr stage 1 to 4 Exclusion Criteria: * Height smaller than 152 cm * Severe vascular conditions of the lower limbs that may limit mobility or pose a risk. * Presence of any implantable or external life-sustaining medical device such as a pacemaker * Severe osteoporosis or high risk of fractures * Contra-indication to the required physical effort * Severe cognitive impairment (MoCA \< 21) * Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility, other than Parkinson's disease. Healthy elderly participants without Parkinson's disease Inclusion Criteria: * Ability to walk for at least 30 minutes with or without minimal aid * Age ≥ 65 years old Exclusion Criteria: * Height smaller than 152 cm * Severe vascular conditions of the lower limbs that may limit mobility or pose a risk. * Presence of any implantable or external life-sustaining medical device such as a pacemaker * Severe osteoporosis or high risk of fractures * Contra-indication to the required physical effort * Severe cognitive impairment (MoCA \< 21) * Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
TechCare Research Lab - CISSS de l'Outaouais Gatineau Quebec Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07567482 on ClinicalTrials.gov ↗ ← All trials in Canada